/ /

  • linkedin
  • Increase Font
  • Sharebar

    Sustained drug delivery moving toward clinical use


    SKS Ocular

    SKS uses micro-molds to build bioerodable polymers using gelatin hydrogels. The gels can be layered with multiple drugs released at different rates, according to Barbara Wirostko, MD, chief medical officer of the glaucoma program.

    “Glaucoma is our most advanced product,” Dr. Wirostko said. “We have high drug-loading capabilities that can be injected with small needles for long-term sustained release. Sustained delivery is the delivery system of the future for ophthalmic care.”

    Other vehicles are being tested for AMD, retinal vein occlusion, diabetic macular edema, and other conditions.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results